Abl Bio Inc.

Yuhan Corporation

Youngdon Pak

Yangsoon Lee

Yeunju Kim

Hyejin Chung

Byungje Sung

Eunsil Sung

Eunyoung Park

Kyungjin Park

Kyeongsu Park

Jinhyung Ahn

Daehae Song

Uijung Jung

Sang Hoon Lee

Juhee Kim

Eun-Jung Lee

Donghoon Yeom

Yong-Gyu Son

Jaehyun Eom

Jaeho Jung

Ui-Jung Jung

Seawon Ahn

YoungKwang Kim

Dongin Kim

Lei Fang

Bora Lee

Moo Young Song

Wenqing Jiang

Jiseon Yoo

Na Rae Lee

Minji Park

Young Bong Park

Jinwon Jung

Hyoju Choi

Yeryoung Yong

Wonjun Son

Sungwon An

Weon-Kyoo You

Sang-Jun Ha

Myeong Joon Kim

Yoseob Lee

Weonkyoo You

Yeun Ju Kim

Jun Hyun Jeong

Provided is an anti-4-1BB antibody or an antigen-binding fragment thereof, and uses thereof.

Anti-4-1BB antibody and use thereof

The present disclosure provides an anti-PD-L1/anti-LAG3 bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between LAG3 and its ligand (e.g., a MHC class II molecule and FGL1). The bispecific antibody may have high binding affinity to both of a PD-L1 protein (e.g., a human PD-L1 protein) and a LAG3 protein (e.g., a human LAG3 protein). Also provided are antibodies and fragments that have specificity to the PD-L1 or LAG3 protein alone, or antibodies and fragments having additional specificity to one or more other antigens.

Anti-PD-L1/anti-LAG3 bispecific antibodies and uses thereof

Provided are an anti-4-1BB/anti-EGFR bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

Anti-EGFR/anti-4-1BB bispecific antibody

The present invention discloses an anti-ROR1 antibody specifically recognizing human and mouse ROR1. The monoclonal antibody can be usefully used for cancer targeting treatment including detection of various cancer expressing ROR1 through specific binding, and drug delivery to specific cancer, etc. as well as a cancer therapeutic agent, by inhibiting tumors.

Anti-ROR1 antibody and use thereof

The present invention relates to a bi-specific antibody that specifically binds to alpha-synuclein and IGF1R, and use of the bi-specific antibody for treating or diagnosing synucleinopathies associated with alpha-synuclein or alpha-synuclein aggregates. The IGF1R portion of the bi-specific antibody acts as a shuttle to penetrate the blood brain barrier, allowing the alpha-synuclein portion to exert its action in the brain. Further, the half-life of the bi-specific antibody may be extended to maintain efficacy over time.

Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof

Provided is an anti-B7-H3 antibody specifically recognizing a B7-H3, which can be usefully as a cancer therapeutic agent, as having an inhibitory activity of an immune checkpoint which induces antibody-dependent cell-mediated cytotoxicity and T cell activation inhibited by B7-H3. In particular, the antibody having the inhibitory activity of an immune checkpoint can be used in combination with other immunoantibody therapeutic agents. In addition, it can be usefully used for cancer targeting treatment including detection of various cancers expressing B7-H3 through specific binding to B7-H3, and drug delivery to specific cancer, etc.

Anti-B7-H3 antibody and use thereof

Growing community of inventors

Seongnam-si, South Korea

Youngdon Pak